Cargando…
Presentation and management of docetaxel-related adverse effects in patients with breast cancer
The taxane chemotherapeutic agent docetaxel has been utilized in the management of breast cancer in the adjuvant, neoadjuvant and metastatic setting. Although well tolerated by the majority of patients, docetaxel toxicity may limit the dose which can be administered. Adverse events include infusion...
Autores principales: | Ho, Maria Y, Mackey, John R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041377/ https://www.ncbi.nlm.nih.gov/pubmed/24904223 http://dx.doi.org/10.2147/CMAR.S40601 |
Ejemplares similares
-
Benefit risk assessment and update on the use of docetaxel in the management of breast cancer
por: Alken, Scheryll, et al.
Publicado: (2013) -
Weekly docetaxel in the treatment of metastatic breast cancer
por: Palmeri, Laura, et al.
Publicado: (2008) -
Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
por: Pant, Shubham, et al.
Publicado: (2008) -
Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer
por: Rajappa, Senthil, et al.
Publicado: (2018) -
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)